News & Updates

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.

Adalimumab for the treatment of hidradenitis suppurativa appears to be less effective in patients with obesity, a study has found.

YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.

Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.

The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.

Proton pump inhibitor (PPI) therapy does not appear to put individuals who require gastric acid suppression at increased risk of gastric cancer, according to a study.